Su Zhan, Liu Sha, Wang Jiulan, Jin Fengying, Peng Youjin, Wen Junjie
Guang'an People's Hospital, Guangan, China.
Abdom Radiol (NY). 2025 Mar 27. doi: 10.1007/s00261-025-04908-w.
To assess the advantages of High-Intensity Focused Ultrasound (HIFU) in the treatment of uterine leiomyomas and adenomyosis.
Patients with uterine leiomyomas (435 cases) and adenomyosis (78 cases) treated in our hospital from March 2020 to October 2023 were selected to receive non-invasive treatment with HIFU. Clinical symptom improvement and fibroid shrinkage were observed, and the incidence of complications and adverse reactions during and after treatment were analyzed.
The success rate of HIFU treatment in 435 cases of uterine leiomyomas was as high as 94.71%. The success rate of HIFU treatment was 96.15% in 78 cases of adenomyosis. Compared with before treatment, the improvement of clinical symptoms and the reduction of leiomyomas at one month, three months and six months after treatment were relatively better than those at the treatment period (P < 0.05). There were no serious adverse reactions in the patients during the treatment.
The noninvasive application of HIFU on leiomyomas and adenomyosis effectively improves the clinical symptoms of patients, and the volume of fibroids decreases significantly. At the same time, HIFU is safe and worthy of clinical application.
评估高强度聚焦超声（HIFU）治疗子宫肌瘤和子宫腺肌病的优势。
选取2020年3月至2023年10月在我院接受治疗的子宫肌瘤患者（435例）和子宫腺肌病患者（78例），采用HIFU进行无创治疗。观察临床症状改善情况及肌瘤缩小情况，并分析治疗期间及治疗后的并发症和不良反应发生率。
435例子宫肌瘤患者的HIFU治疗成功率高达94.71%。78例子宫腺肌病患者的HIFU治疗成功率为96.15%。与治疗前相比，治疗后1个月、3个月和6个月时临床症状的改善及肌瘤缩小情况均优于治疗期间（P < 0.05）。治疗期间患者未出现严重不良反应。
HIFU无创应用于子宫肌瘤和子宫腺肌病可有效改善患者临床症状，肌瘤体积显著减小。同时，HIFU安全，值得临床应用。
